ChinaBio Securities-B (02509.HK) announced that the II clinical trial data of QX005N injection for treating nodular prurigo (PN) was presented at the 29th Chinese Medical Association Dermatology Conference in the form of oral report. Based on the trial data, QX005N was included in the breakthrough therapy product list by the National Medical Products Administration Drug Evaluation Center on January 31 this year.

This trial is the first domestic biopharmaceutical clinical trial conducted by a mainland enterprise for the indication of PN. The research results showed that the main endpoint of each dosage group in this clinical trial was completely achieved.